Latest Janssen Pharmaceutica Stories
The Firm is representing Risperdal lawsuit plaintiffs who allegedly experienced gynecomastia, or male breast growth, due to their use of the antipsychotic medication. New
Demonstrates ongoing commitment to address the world's most pressing health care needs NEW BRUNSWICK, N.J., May 20, 2015 /PRNewswire/ -- At a meeting today with industry analysts,
TITUSVILLE, N.J., May 19, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc.
HedgePath to shortly commence Phase II(b) skin cancer trial using Mayne Pharma's SUBA(TM)-Itraconazole TAMPA, Fla.
NEW BRUNSWICK, N.J., May 7, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced a first-of-its-kind partnership that enlists a third party to review requests made to the Janssen
Clinical Data from Two Different Development Programs Highlight Efficacy and Tolerability of Sublingual Sufentanil in Out-patient and In-patient Surgical Populations REDWOOD CITY,
Bernstein Liebhard LLP is representing numerous plaintiffs who have filed Risperdal lawsuits in the Pennsylvania litigation, all of whom allegedly developed gynecomastia (male breast growth) due
Bernstein Liebhard LLP is representing numerous Risperdal plaintiffs in the Pennsylvania litigation, all of whom allegedly experienced excessive male breast growth due to their use of the antipsychotic
PHILADELPHIA, March 20, 2015 /PRNewswire/ -- A Philadelphia jury today affirmed by a 10-2 vote that Janssen Pharmaceuticals, a division of Johnson & Johnson, failed to warn of the risk to
AcelRx Announces Restructuring to Focus on Regulatory Approval of Zalviso and Clinical Development of ARX-04 REDWOOD CITY, Calif., March 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
- A woman chauffeur.
- A woman who operates an automobile.